GLENMARK PHARMACEUTICALS vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of GLENMARK PHARMACEUTICALS (GLENMARK) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, GLENMARK PHARMACEUTICALS leads GLENMARK vs TORNTPHARM on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability22
  • Growth20
  • Size & financial health22
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

50.87
P/E ratio
77.50
5.90
P/B ratio
18.67
0.20%
Dividend yield
0.76%
₹48.26
EPS
₹63.92

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

30.50%
Return on equity
27.40%
40.00%
Return on capital
15.00%
27.00%
EBITDA margin
33.00%
8.02%
Net margin
15.29%

Growth

GLENMARK takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

13.61%
Revenue CAGR (3Y)
13.27%
53.44%
Profit CAGR (3Y)
19.75%

Size & financial health

Even

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹69,740 Cr
Market cap
₹1.68L Cr
₹16,983 Cr
Revenue
₹13,980 Cr
₹1,362 Cr
Net profit
₹2,138 Cr
0.00
Debt / equity
1.69
GLENMARK PHARMACEUTICALS
  • + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 19.4% CAGR over last 5 years"]
  • ["The company has delivered a poor sales growth of 9.19% over past five years.", "Company has a low return on equity of -3.28% over last 3 years.", "Debtor days have increased from 85.2 to 107 days.", "Working capital days have increased from 41.2 days to 80.5 days"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
GLENMARK PHARMACEUTICALS full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

GLENMARK vs TORNTPHARM: Share Price, Valuation & Which to Buy | DocStoX